Patentability of AI-Discovered Medicines: Navigating Legal Frameworks and Clinical Progress
The AI drug discovery sector achieved its first major clinical validation in 2025 with Insilico Medicine's rentosertib becoming
The Weekly Term Sheet (39)
Biotech dealmaking surged this week, from Pfizer’s $7.3 billion obesity acquisition to a run of licensing, royalty financings,
Milestone Payments in Pharma & Biotech Licensing Deals
Overview
Milestone payments are contingent fees in pharmaceutical and biotech deals that become due when a product achieves specific goals.
Company of the week: Revolution Medicines
Introduction and Company Overview
Revolution Medicines (NASDAQ: RVMD) is a late-stage oncology biotech focused on targeting the RAS oncogene family,
Fund of the week: Breakout Ventures
Executive Summary
Breakout Ventures is a San Francisco-based venture capital firm specializing in life sciences and "deep tech"
Biotech Venture Debt: Technical Analysis of Deal Structuring and Covenant Architecture
Current Market Dynamics and Transaction Volume
The biotech venture debt market underwent substantial transformation following the Silicon Valley Bank collapse
PIPEs in Biopharma: A 2025 Deep Dive
The biopharma sector in 2025 is navigating a difficult funding landscape. Public markets have cooled off after the boom of
Disease-Linked Bonds: Cancer Bonds and Pandemic Bonds – A Comprehensive Analysis
1. Historical Examples of Disease-Linked Bonds
Pandemic Bonds (World Bank PEF)
The most prominent example is the World Bank'
The weekly term sheet (38)
The week of September 15-20, 2025 witnessed over 40 distinct biotech pharmaceutical transactions totaling more than $6 billion in disclosed
The Great AI Wrapper Charade in Biotech
In boardrooms and biotech conferences alike, one phrase has become inescapable: “our AI-powered platform.” Startups in drug discovery, clinical decision
